Clinical trial
PS-341 in Treating Women With Metastatic Breast Cancer
NCT00025584 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00025584 |
|---|---|
| Title | PS-341 in Treating Women With Metastatic Breast Cancer |
| Official title | Phase II Trial Of PS-341 In Metastatic Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Drug, Other |
| Interventions | bortezomib, laboratory biomarker analysis |
| Enrollment | 35 |
| Start date | Aug 1, 2001 |
| Primary completion | Aug 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: